MedTrace Logo

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

NCT01320085 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2024-01-24

Study results available
· View outcomes & findings →

Summary

The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.

Conditions

  • BRAF or NRAS Mutant Metastatic Melanoma

Interventions

DRUG

MEK162

Sponsors & Collaborators

Principal Investigators

  • Pfizer Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-24
Primary Completion
2014-01-07
Completion
2023-02-06

Countries

  • United States
  • Germany
  • Italy
  • Netherlands
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01320085 on ClinicalTrials.gov